Alphatec lowers FY 2026 revenue outlook to $862M while targeting 16% adjusted EBITDA margin (NASDAQ:ATEC)
Alphatec (ATEC) reported Q3 2026 revenue of $221M, up 13% YoY, but below expectations. The company lowered its FY 2026 revenue outlook to $862M and targets a 16% adjusted EBITDA margin. Management cited strong demand for surgical solutions.
How this was made
The 30-second read
Why it matters
The reduced FY 2026 revenue outlook could trigger a sell‑off, while the Q3 growth may temper the decline.
Market read
Guidance cut is a primary corporate event that can move the stock and affect the medical‑device sector.
What to watch
Strong demand for surgical solutions and 13% Q3 revenue growth may indicate resilience despite lower FY outlook.
Background
Alphatec Holdings provides surgical devices and reported Q3 results with revenue growth, but lowered its full‑year revenue guidance.
Ticker impact
Alphatec lowered its FY 2026 revenue outlook to $862M and reported Q3 revenue of $221M, up 13% YoY.
downward pressure as the market prices in the reduced revenue outlook
Revenue guidance drop suggests lower earnings potential, prompting investors to reassess valuation.
Market effects
Medical‑device sector may face slight headwinds as a peer's guidance is cut.
U.S. small‑cap market could see modest downside pressure.
Limited to U.S. equities; no broader macro impact.
Counterpoint
The guidance cut may be temporary; upcoming product launches could offset revenue shortfall.
Key entities
- CompanyAlphatec Holdings
Medical‑device manufacturer
- ExecutivePatrick Miles
Chairman, CEO & President of Alphatec



